Close Menu

NEW YORK (GenomeWeb) – Despite high hopes and significant investment, plasma proteomics has thus far yielded little in the way of useful protein biomarkers. Only a handful of new protein markers and proteomic tests have made it to the clinic over the last decade, and even fewer have succeeded in achieving broad clinical adoption and commercial viability.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

According to NPR, an antibody-based test could identify people who were exposed to SARS-CoV-2 and either didn't develop symptoms or were misdiagnosed.

A sequencing analysis of New York City rats indicates they have adapted to the urban environment there, according to a recent preprint.

Ars Technica reports that a multicellular eukaryotic parasite has lost its mitochondria.

In Science this week: perspective piece says AI can accelerate drug discovery by using genomic and chemical data, and more.

Mar
31
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.